洞察市场格局
解锁药品研发情报

免费客服电话

18983288589
试用企业版

【ChiCTR2400090027】Self compassion, post-traumatic growth and body image of women with breast cancer

基本信息
登记号

ChiCTR2400090027

试验状态

尚未开始

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2024-09-23

临床申请受理号

/

靶点

/

适应症

breast cancer

试验通俗题目

Self compassion, post-traumatic growth and body image of women with breast cancer

试验专业题目

Body image and post-traumatic growth in women with breast cancer: self compassion as mediator and intervention

申办单位信息
申请人联系人
申请人名称
联系人邮箱
联系人邮编

联系人通讯地址
临床试验信息
试验目的

Hypothesis 1: Body image distress is inversely related to self-compassion and positively related to psychological distress Hypothesis 2: Self-compassion is positively related to post-traumatic growth Hypothesis 3: Self-compassion mediates the relationship between body image and posttraumatic growth. Hypothesis 4: Women with breast cancer assigned the self-compassion intervention group will report increased self-compassion, reduced body image distress, increased post traumatic growth, reduced psychological distress compared to the control group. reduced psychological distress compared to the control group.

试验分类
试验类型

随机平行对照

试验分期

探索性研究/预试验

随机化

Random number table

盲法

Not stated

试验项目经费来源

None

试验范围

/

目标入组人数

54;131

实际入组人数

/

第一例入组时间

2024-10-01

试验终止时间

2025-09-30

是否属于一致性

/

入选标准

Inclusion criteria for both study 1 and study 2 include being 18 years old or older, identifying as a woman, ability to read Chinese and understand Cantonese, first-time clinical diagnosis of stage I-III breast malignancies, and being in the medical treatment phase for cancer. Additional inclusion criteria for study 2 include access to the internet, willingness to attend all the group sessions, experiencing body image distress (i.e. self-reported Body Image Scale (BSI) score >= 10).;

排除标准

For both study 1 and study 2, individuals with other types of primary cancers will be excluded. Additional exclusion criteria for study 2 include past or current involvement in self-compassion intervention, regular practice of meditation in the past 6 months, cognitive impairment, and history of serious mental health disorders such as bipolar disorder and schizophrenia-spectrum disorders.;

研究者信息
研究负责人姓名
试验机构

The University of Hong Kong

研究负责人电话
研究负责人邮箱
研究负责人邮编

/

联系人通讯地址
<END>

The University of Hong Kong的其他临床试验

The University of Hong Kong的其他临床试验

最新临床资讯

对摩熵医药数据库感兴趣,可以免费体验产品